Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $37.1 million.

  • Eton Pharmaceuticals' Cash & Equivalents rose 83.21% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year increase of 83.21%. This contributed to the annual value of $14.9 million for FY2024, which is 30.17% down from last year.
  • Per Eton Pharmaceuticals' latest filing, its Cash & Equivalents stood at $37.1 million for Q3 2025, which was up 46.27% from $25.4 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Cash & Equivalents high stood at $37.1 million for Q3 2025, and its period low was $13.4 million during Q3 2022.
  • For the 3-year period, Eton Pharmaceuticals' Cash & Equivalents averaged around $20.8 million, with its median value being $20.3 million (2024).
  • Per our database at Business Quant, Eton Pharmaceuticals' Cash & Equivalents skyrocketed by 209.72% in 2021 and then crashed by 41.09% in 2022.
  • Over the past 5 years, Eton Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $14.4 million in 2021, then grew by 13.18% to $16.3 million in 2022, then soared by 31.17% to $21.4 million in 2023, then crashed by 30.17% to $14.9 million in 2024, then soared by 83.21% to $37.1 million in 2025.
  • Its Cash & Equivalents stands at $37.1 million for Q3 2025, versus $25.4 million for Q2 2025 and $17.4 million for Q1 2025.